Khiron Life Sciences (TSXV: KHRN) announced this morning that it now has access to yet another medical cannabis market: Peru. Khiron has received all required licenses and authorizations for the import and commercialization of full spectrum, high-CBD medical cannabis productions.
The products will be imported to Peru from that of Khiron Colombia, with the product then being manufactured and distributed to patients within the country by that of Farmacia Universal under a previously announced arrangement.
While currently approved for the import and sale of full spectrum high-CBD medical cannabis products, Khiron is also working towards receiving approvals from the Directorate General of Drug Supplies and Drugs (DIGEMID), the governing body in Peru, for the import and commercialization of high-THC medical cannabis products. The company currently anticipates this approval to be received in the fourth quarter of 2020.
With these authorizations, Khiron Peru is now able to begin importing high-CBD product from that of Khiron Colombia. The first prescriptions are able to be filled in the third quarter of 2020. Notably, the authorizations have arrived as the company surpasses the 1,000 patient prescription milestone in Colombia.
Khiron Life Sciences last traded at $0.50 on the TSX Venture.
FULL DISCLOSURE: Khiron Life Sciences is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Khiron Life Sciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
